Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Castle Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Castle Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a OCF Margin % of 14.68% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #74 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 36.5%.
Is Castle Biosciences' OCF Margin % too high?
Castle Biosciences' current OCF Margin % is 14.68%. The Medical Diagnostics & Research industry median OCF Margin % is 5.53. Castle Biosciences' value of 14.68% is 165.5% above this industry median. Based on the distribution chart, Castle Biosciences ranks #74 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' OCF Margin % compare to OPK and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #74 out of 203 companies for OCF Margin %. This puts Castle Biosciences in the upper half of its industry. The industry median OCF Margin % is 5.53. Castle Biosciences' value of 14.68% is 165.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 5.53, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current OCF Margin % of 14.68% is 165.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current OCF Margin % is 14.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Fairly Valued. The stock's GF Value™ is $29.71, compared to a current price of $32.01 — trading 7.7% above its estimated fair value. The current OCF Margin % is 14.68% and 165.5% above the Medical Diagnostics & Research industry median of 5.53. Castle Biosciences' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current OCF Margin % is 14.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued.
The current stock price of $32.01 is trading 7.7% above its estimated GF Value™ of $29.71.
GuruFocus considers Castle Biosciences to be Fairly Valued.
Key valuation signals for CSTL:
OCF Margin %: 14.68%
GF Value™: $29.71 vs. price of $32.01 (7.7% above fair value)
Industry Position: 165.5% above the Medical Diagnostics & Research median (#74 of 203)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
80GF Score
Get the complete analysis for CSTL
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
